Letters

Volume 31—2025

Volume 30—2024

Volume 29—2023

Volume 28—2022

Volume 27—2021

Volume 26—2020

Volume 25—2019

Volume 24—2018

Volume 23—2017

Volume 22—2016

Volume 21—2015

Volume 20—2014

Volume 19—2013

Volume 18—2012

Volume 17—2011

Volume 16—2010

Volume 15—2009

Volume 14—2008

Volume 13—2007

Volume 12—2006

Volume 11—2005

Volume 10—2004

Volume 9—2003

Volume 8—2002

Volume 7—2001

Volume 6—2000

Volume 5—1999

Volume 4—1998

Volume 3—1997

Volume 2—1996

Volume 1—1995

Volume 28—2022

Volume 28, Number 12—December 2022

Hand, Foot, and Mouth Disease as Differential Diagnosis of Monkeypox, Germany, August 2022 [PDF - 493 KB - 1 page]

A. Fathi and S. Schmiedel

EID	Fathi A, Schmiedel S. Hand, Foot, and Mouth Disease as Differential Diagnosis of Monkeypox, Germany, August 2022. Emerg Infect Dis. 2022;28(12):2586. https://doi.org/10.3201/eid2812.221487
AMA	Fathi A, Schmiedel S. Hand, Foot, and Mouth Disease as Differential Diagnosis of Monkeypox, Germany, August 2022. Emerging Infectious Diseases. 2022;28(12):2586. doi:10.3201/eid2812.221487.
APA	Fathi, A., & Schmiedel, S. (2022). Hand, Foot, and Mouth Disease as Differential Diagnosis of Monkeypox, Germany, August 2022. Emerging Infectious Diseases, 28(12), 2586. https://doi.org/10.3201/eid2812.221487.

Volume 28, Number 8—August 2022

Seroprevalence of Chikungunya Virus, Jamaica, and New Tools for Surveillance [PDF - 233 KB - 2 pages]

A. Freitas et al.

EID	Freitas A, Pezzi L, Cavalcanti L, Simon F. Seroprevalence of Chikungunya Virus, Jamaica, and New Tools for Surveillance. Emerg Infect Dis. 2022;28(8):1736-1737. https://doi.org/10.3201/eid2808.220558
AMA	Freitas A, Pezzi L, Cavalcanti L, et al. Seroprevalence of Chikungunya Virus, Jamaica, and New Tools for Surveillance. Emerging Infectious Diseases. 2022;28(8):1736-1737. doi:10.3201/eid2808.220558.
APA	Freitas, A., Pezzi, L., Cavalcanti, L., & Simon, F. (2022). Seroprevalence of Chikungunya Virus, Jamaica, and New Tools for Surveillance. Emerging Infectious Diseases, 28(8), 1736-1737. https://doi.org/10.3201/eid2808.220558.

Seroprevalence of Chikungunya Virus, Jamaica, and New Tools for Surveillance (Response) [PDF - 236 KB - 2 pages]

J. J. Anzinger

EID	Anzinger JJ. Seroprevalence of Chikungunya Virus, Jamaica, and New Tools for Surveillance (Response). Emerg Infect Dis. 2022;28(8):1737-1738. https://doi.org/10.3201/eid2808.221006
AMA	Anzinger JJ. Seroprevalence of Chikungunya Virus, Jamaica, and New Tools for Surveillance (Response). Emerging Infectious Diseases. 2022;28(8):1737-1738. doi:10.3201/eid2808.221006.
APA	Anzinger, J. J. (2022). Seroprevalence of Chikungunya Virus, Jamaica, and New Tools for Surveillance (Response). Emerging Infectious Diseases, 28(8), 1737-1738. https://doi.org/10.3201/eid2808.221006.

Imported Monkeypox from International Traveler, Maryland, USA, 2021 [PDF - 227 KB - 1 page]

F. S. Minhaj et al.

EID	Minhaj FS, Rao AK, McCollum AM. Imported Monkeypox from International Traveler, Maryland, USA, 2021. Emerg Infect Dis. 2022;28(8):1738. https://doi.org/10.3201/eid2808.220726
AMA	Minhaj FS, Rao AK, McCollum AM. Imported Monkeypox from International Traveler, Maryland, USA, 2021. Emerging Infectious Diseases. 2022;28(8):1738. doi:10.3201/eid2808.220726.
APA	Minhaj, F. S., Rao, A. K., & McCollum, A. M. (2022). Imported Monkeypox from International Traveler, Maryland, USA, 2021. Emerging Infectious Diseases, 28(8), 1738. https://doi.org/10.3201/eid2808.220726.

Imported Monkeypox from International Traveler, Maryland, USA, 2021 (Response) [PDF - 208 KB - 1 page]

V. Costello et al.

EID	Costello V, Sowash M, Gaur A, Cardis M, Pasieka H, Wortmann G, et al. Imported Monkeypox from International Traveler, Maryland, USA, 2021 (Response). Emerg Infect Dis. 2022;28(8):1739. https://doi.org/10.3201/eid2808.220830
AMA	Costello V, Sowash M, Gaur A, et al. Imported Monkeypox from International Traveler, Maryland, USA, 2021 (Response). Emerging Infectious Diseases. 2022;28(8):1739. doi:10.3201/eid2808.220830.
APA	Costello, V., Sowash, M., Gaur, A., Cardis, M., Pasieka, H., Wortmann, G....Ramdeen, S. (2022). Imported Monkeypox from International Traveler, Maryland, USA, 2021 (Response). Emerging Infectious Diseases, 28(8), 1739. https://doi.org/10.3201/eid2808.220830.

Volume 28, Number 6—June 2022

Association of Healthcare and Aesthetic Procedures with Infections Caused by Nontuberculous Mycobacteria, France, 2012–2020 [PDF - 510 KB - 2 pages]

K. X. McNamara et al.

EID	McNamara KX, Perz JF, Perkins KM. Association of Healthcare and Aesthetic Procedures with Infections Caused by Nontuberculous Mycobacteria, France, 2012–2020. Emerg Infect Dis. 2022;28(6):1303. https://doi.org/10.3201/eid2806.220520
AMA	McNamara KX, Perz JF, Perkins KM. Association of Healthcare and Aesthetic Procedures with Infections Caused by Nontuberculous Mycobacteria, France, 2012–2020. Emerging Infectious Diseases. 2022;28(6):1303. doi:10.3201/eid2806.220520.
APA	McNamara, K. X., Perz, J. F., & Perkins, K. M. (2022). Association of Healthcare and Aesthetic Procedures with Infections Caused by Nontuberculous Mycobacteria, France, 2012–2020. Emerging Infectious Diseases, 28(6), 1303. https://doi.org/10.3201/eid2806.220520.

Association of Healthcare and Aesthetic Procedures with Infections Caused by Nontuberculous Mycobacteria, France, 2012‒2020 (response) [PDF - 510 KB - 2 pages]

C. Daniau et al.

EID	Daniau C, Berger-Carbonne A, Cambau E. Association of Healthcare and Aesthetic Procedures with Infections Caused by Nontuberculous Mycobacteria, France, 2012‒2020 (response). Emerg Infect Dis. 2022;28(6):1303-1304. https://doi.org/10.3201/eid2806.220686
AMA	Daniau C, Berger-Carbonne A, Cambau E. Association of Healthcare and Aesthetic Procedures with Infections Caused by Nontuberculous Mycobacteria, France, 2012‒2020 (response). Emerging Infectious Diseases. 2022;28(6):1303-1304. doi:10.3201/eid2806.220686.
APA	Daniau, C., Berger-Carbonne, A., & Cambau, E. (2022). Association of Healthcare and Aesthetic Procedures with Infections Caused by Nontuberculous Mycobacteria, France, 2012‒2020 (response). Emerging Infectious Diseases, 28(6), 1303-1304. https://doi.org/10.3201/eid2806.220686.

Volume 28, Number 5—May 2022

Guillain-Barré Syndrome Associated with COVID-19 Vaccination [PDF - 237 KB - 2 pages]

J. Finsterer et al.

EID	Finsterer J, Scorza FA, Scorza CA. Guillain-Barré Syndrome Associated with COVID-19 Vaccination. Emerg Infect Dis. 2022;28(5):1079-1080. https://doi.org/10.3201/eid2805.212145
AMA	Finsterer J, Scorza FA, Scorza CA. Guillain-Barré Syndrome Associated with COVID-19 Vaccination. Emerging Infectious Diseases. 2022;28(5):1079-1080. doi:10.3201/eid2805.212145.
APA	Finsterer, J., Scorza, F. A., & Scorza, C. A. (2022). Guillain-Barré Syndrome Associated with COVID-19 Vaccination. Emerging Infectious Diseases, 28(5), 1079-1080. https://doi.org/10.3201/eid2805.212145.

SARS-CoV-2 Cross-Reactivity in Prepandemic Serum from Rural Malaria-Infected Persons, Cambodia [PDF - 237 KB - 2 pages]

J. T. Grassia et al.

EID	Grassia JT, Markwalter CF, O’Meara WP, Taylor SM, Obala AA. SARS-CoV-2 Cross-Reactivity in Prepandemic Serum from Rural Malaria-Infected Persons, Cambodia. Emerg Infect Dis. 2022;28(5):1080-1081. https://doi.org/10.3201/eid2805.220404
AMA	Grassia JT, Markwalter CF, O’Meara WP, et al. SARS-CoV-2 Cross-Reactivity in Prepandemic Serum from Rural Malaria-Infected Persons, Cambodia. Emerging Infectious Diseases. 2022;28(5):1080-1081. doi:10.3201/eid2805.220404.
APA	Grassia, J. T., Markwalter, C. F., O’Meara, W. P., Taylor, S. M., & Obala, A. A. (2022). SARS-CoV-2 Cross-Reactivity in Prepandemic Serum from Rural Malaria-Infected Persons, Cambodia. Emerging Infectious Diseases, 28(5), 1080-1081. https://doi.org/10.3201/eid2805.220404.

Melioidosis in Children, Brazil, 1989–2019 [PDF - 237 KB - 2 pages]

B. Behera et al.

EID	Behera B, Radhakrishnan A, Mohapatra S, Mishra B. Melioidosis in Children, Brazil, 1989–2019. Emerg Infect Dis. 2022;28(5):1081-1082. https://doi.org/10.3201/eid2805.211473
AMA	Behera B, Radhakrishnan A, Mohapatra S, et al. Melioidosis in Children, Brazil, 1989–2019. Emerging Infectious Diseases. 2022;28(5):1081-1082. doi:10.3201/eid2805.211473.
APA	Behera, B., Radhakrishnan, A., Mohapatra, S., & Mishra, B. (2022). Melioidosis in Children, Brazil, 1989–2019. Emerging Infectious Diseases, 28(5), 1081-1082. https://doi.org/10.3201/eid2805.211473.

Melioidosis in Children, Brazil, 1989–2019 (response) [PDF - 212 KB - 1 page]

R. Lima and D. Rolim

EID	Lima R, Rolim D. Melioidosis in Children, Brazil, 1989–2019 (response). Emerg Infect Dis. 2022;28(5):1081-1082. https://doi.org/10.3201/eid2805.220479
AMA	Lima R, Rolim D. Melioidosis in Children, Brazil, 1989–2019 (response). Emerging Infectious Diseases. 2022;28(5):1081-1082. doi:10.3201/eid2805.220479.
APA	Lima, R., & Rolim, D. (2022). Melioidosis in Children, Brazil, 1989–2019 (response). Emerging Infectious Diseases, 28(5), 1081-1082. https://doi.org/10.3201/eid2805.220479.

High-Dose Convalescent Plasma for Treatment of Severe COVID-19 [PDF - 197 KB - 1 page]

D. Focosi and A. Casadevall

EID	Focosi D, Casadevall A. High-Dose Convalescent Plasma for Treatment of Severe COVID-19. Emerg Infect Dis. 2022;28(5):1083. https://doi.org/10.3201/eid2805.220191
AMA	Focosi D, Casadevall A. High-Dose Convalescent Plasma for Treatment of Severe COVID-19. Emerging Infectious Diseases. 2022;28(5):1083. doi:10.3201/eid2805.220191.
APA	Focosi, D., & Casadevall, A. (2022). High-Dose Convalescent Plasma for Treatment of Severe COVID-19. Emerging Infectious Diseases, 28(5), 1083. https://doi.org/10.3201/eid2805.220191.

High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response) [PDF - 206 KB - 2 pages]

G. C. De Santis and R. T. Calado

EID	De Santis GC, Calado RT. High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response). Emerg Infect Dis. 2022;28(5):1083-1084. https://doi.org/10.3201/eid2805.220363
AMA	De Santis GC, Calado RT. High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response). Emerging Infectious Diseases. 2022;28(5):1083-1084. doi:10.3201/eid2805.220363.
APA	De Santis, G. C., & Calado, R. T. (2022). High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response). Emerging Infectious Diseases, 28(5), 1083-1084. https://doi.org/10.3201/eid2805.220363.

Volume 28, Number 3—March 2022

Addendum to Proposal for Human Respiratory Syncytial Virus Nomenclature below the Species Level [PDF - 691 KB - 1 page]

I. G. Barr et al.

EID	Barr IG, Williams TC, Salimi V, Buchholz UJ. Addendum to Proposal for Human Respiratory Syncytial Virus Nomenclature below the Species Level. Emerg Infect Dis. 2022;28(3):764. https://doi.org/10.3201/eid2803.212438
AMA	Barr IG, Williams TC, Salimi V, et al. Addendum to Proposal for Human Respiratory Syncytial Virus Nomenclature below the Species Level. Emerging Infectious Diseases. 2022;28(3):764. doi:10.3201/eid2803.212438.
APA	Barr, I. G., Williams, T. C., Salimi, V., & Buchholz, U. J. (2022). Addendum to Proposal for Human Respiratory Syncytial Virus Nomenclature below the Species Level. Emerging Infectious Diseases, 28(3), 764. https://doi.org/10.3201/eid2803.212438.

Volume 28, Number 2—February 2022

High Infection Attack Rate after SARS-CoV-2 Delta Surge, Chattogram, Bangladesh [PDF - 1.01 MB - 2 pages]

S. T. Hegde et al.

EID	Hegde ST, Bhuiyan T, Akhtar M, Islam T, Hulse J, Khan Z, et al. High Infection Attack Rate after SARS-CoV-2 Delta Surge, Chattogram, Bangladesh. Emerg Infect Dis. 2022;28(2):491-492. https://doi.org/10.3201/eid2802.212417
AMA	Hegde ST, Bhuiyan T, Akhtar M, et al. High Infection Attack Rate after SARS-CoV-2 Delta Surge, Chattogram, Bangladesh. Emerging Infectious Diseases. 2022;28(2):491-492. doi:10.3201/eid2802.212417.
APA	Hegde, S. T., Bhuiyan, T., Akhtar, M., Islam, T., Hulse, J., Khan, Z....Qadri, F. (2022). High Infection Attack Rate after SARS-CoV-2 Delta Surge, Chattogram, Bangladesh. Emerging Infectious Diseases, 28(2), 491-492. https://doi.org/10.3201/eid2802.212417.

Predictors of Nonseroconversion after SARS-CoV-2 Infection [PDF - 618 KB - 2 pages]

B. Davido et al.

EID	Davido B, Jaffal K, Annane D, Lawrence C, Gault E, De P. Predictors of Nonseroconversion after SARS-CoV-2 Infection. Emerg Infect Dis. 2022;28(2):492-493. https://doi.org/10.3201/eid2802.211971
AMA	Davido B, Jaffal K, Annane D, et al. Predictors of Nonseroconversion after SARS-CoV-2 Infection. Emerging Infectious Diseases. 2022;28(2):492-493. doi:10.3201/eid2802.211971.
APA	Davido, B., Jaffal, K., Annane, D., Lawrence, C., Gault, E., & De, P. (2022). Predictors of Nonseroconversion after SARS-CoV-2 Infection. Emerging Infectious Diseases, 28(2), 492-493. https://doi.org/10.3201/eid2802.211971.

Volume 28, Number 1—January 2022

New Delhi Metallo-β-Lactamase-Producing Enterobacterales Bacteria [PDF - 653 KB - 1 page]

Y. Yao et al.

EID	Yao Y, Imirzalioglu C, Falgenhauer L, Chakraborty T. New Delhi Metallo-β-Lactamase-Producing Enterobacterales Bacteria. Emerg Infect Dis. 2022;28(1):265. https://doi.org/10.3201/eid2801.212106
AMA	Yao Y, Imirzalioglu C, Falgenhauer L, et al. New Delhi Metallo-β-Lactamase-Producing Enterobacterales Bacteria. Emerging Infectious Diseases. 2022;28(1):265. doi:10.3201/eid2801.212106.
APA	Yao, Y., Imirzalioglu, C., Falgenhauer, L., & Chakraborty, T. (2022). New Delhi Metallo-β-Lactamase-Producing Enterobacterales Bacteria. Emerging Infectious Diseases, 28(1), 265. https://doi.org/10.3201/eid2801.212106.

Page created: December 03, 2021

Page updated: November 21, 2022

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.